Anne-paule Gimenez-roqueplo
Professor
Genetics
Pheochromocytoma and paraganglioma RESearch Support ORganization
Australia
Biography
Anne-Paule Gimenez-Roqueplo (MD, specialized in Endocrinology, PhD) is Full Professor in the Department of Genetics (Assistance Publique-Hôpitaux de Paris; Hôpital Européen Georges Pompidou) and at Paris Descartes University. She is the leader of an academic research team entitled “Pheochromocytomas and paragangliomas (PCC/PGL), from genetics to molecular targeted therapies” within the INSERM Unit 970 at the Paris Cardiovascular Research Center at HEGP (PARCC@HEGP, Paris, France), which develops a basic, translational and clinical research project dedicated to PCC/PGL Her group established the genetic testing recommendations for patients with PCC/PGL, demonstrated that the identification of a germline SDHB mutation is the first high risk factor of malignancy and of poor prognosis, showed that SDHx-related PCC/PGL are characterized by a stimulation of the hypoxia-angiogenesis pathway and by a hypermethylator phenotype, and published in 2015 the first integrated genomic analysis of a large series of PCC/PGL collected by the COMETE network. Her group develops an integrative genomic approach and different animal and cellular experimental models of malignant PCC/PGL. Her researches are supported by ANR (National Research Agency), the European Union (FP7 & H2020), INCa (National Cancer Institute) and the Ligue Nationale contre le Cancer (National League Against Cancer, ‘Tumor Identity Cards (CIT)’ Programme). She is the past chairman of the Pheochromocytoma-Paraganglioma Research Support Organization (PRESSOR), the head of the Pheochromocytoma working group of the European Network for the Study of Adrenal Tumors (ENS@T) and member of the ENS@T steering committee. She coordinates the COMETE network and the French registry for SDH-related paraganglioma (PGL.R).
Research Interest
Epigenetics Oncology Tumors Genomic Analysis
Publications
-
Rethinking pheochromocytomas and paragangliomas from a genomic perspective.
-
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine.
-
Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas.